APR O L TOTAL STATE OF THE PADE

RP IFW

ROLLING ST	це	PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no	persons are required to respond to a confidence Application Number	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE illection of information unless it displays a valid OMB control number. 10/667,189
TRANSMITTAL	Filing Date	09/17/2003
FORM	First Named Inventor	Michael J. Munchhof
	Art Unit	1625
	Examiner Name	Morris, Patricia L
(to be used for all correspondence after initial filin	Attorney Docket Number	PC25405A
Total Number of Pages in This Submission		1 5257057
	ENCLOSURES (Check all	i that apply)
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application  Reply to Missing Parts	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence of Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Landscape Table on Cl  Remarks	Address Status Letter Other Enclosure(s) (please Identify below):
LJ under 37 CFR 1.52 or 1.53	JRE OF APPLICANT, ATTO	RNEY, OR AGENT
Firm Name Pfizer Inc.		
Signature	10-	
Printed name	s / Sut	
Nicholas J. Sisti	/	
Date April I.	2005	Reg. No. 54, 453
CER	RTIFICATE OF TRANSMISS	ION/MAILING
I hereby certify that this correspondence is bein sufficient postage as first class mail in an enveloped date shown below: Signature	g facsimile transmitted to the USPT ope addressed to: Commissioner fo	O or deposited with the United States Postal Service with r Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name Jaylice Denison		Date 4/1/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner: P. Morris

Group Art Unit: 1625

Confirmation No. 8574

I headby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of April, 2005.

By

(Signature of person fasiling)

Janice Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Munchhof, Michael J., et al.

APPLICATION NO.: 10/667,189 :

FILING DATE: September 17, 2003

TITLE: Novel Pyrazole Compounds As

Transforming Growth Factor (TGF)

Inhibitors

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## Response Under 37 CFR § 1.116

In response to the Final Office Action mailed on March 14, 2005, Applicants respectfully submit that the present invention is in condition for allowance and request reconsideration of the subject application in view of the following amendments and remarks. The response is being filed within the two month shortened statutory period for reply and thus no fee is due.

Amendments to the claims are reflected in the listing of claims which begin on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.